As­traZeneca’s la­bel ex­pan­sion plans for Truqap makes ground in prostate can­cer

Af­ter re­cent­ly dis­con­tin­u­ing R&D for Truqap in triple-neg­a­tive breast can­cer, As­traZeneca has some good news on its ki­nase in­hibitor in a dif­fer­ent in­di­ca­tion.

The UK …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER